Owners, management and financials
CVR: 36945125
Previous names: ApS STAKE nr. 5237, Cortris Nordic ApS, 3B-Oncology ApS
DKK -410,610
Gross profit
Net result: DKK -665,070
TIMPCO-RO ApS (25-33,32%), Alexander Meier Holding ApS (5-9,99%)
1 more
CVR · view owners
Kasper Pasternak Jørgensen, Nils Aage Brünner
CVR · view management
Active
Founded 1 July 2015
CVR · view overview
0 employees
CVR · 2016
Owner registered: TIMPCO-RO ApS
CVR · 01/09/2026
View the full event history
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.
Selskabets formål er at drive virksomhed med produktion, handel og service inden for life science, hvilket efter direktionens bestemmelse kan ske gennem koncernforbundne selskaber samt hermed beslægtet aktivitet
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -411 t. | -665 t. | 536 t. | 326 t. | 2 | |
| 202401/01/2024 – 31/12/2024 | -16 t. | -29 t. | 448 t. | 307 t. | 2 | |
| 202301/01/2023 – 31/12/2023 | -21 t. | -22 t. | 49 t. | -63 t. | 1 | |
| 202201/01/2022 – 31/12/2022 | -12 t. | -10 t. | 7 t. | -41 t. | - | |
| 202101/01/2021 – 31/12/2021 | -10 t. | -9 t. | 6 t. | -31 t. | - | |
| 202001/01/2020 – 31/12/2020 | -10 t. | -8 t. | 6 t. | -23 t. | - | |
| 201901/01/2019 – 31/12/2019 | 14 t. | 10 t. | 8 t. | -15 t. | - | |
| 201801/01/2018 – 31/12/2018 | -15 t. | -13 t. | 43 t. | -25 t. | - | |
| 201701/01/2017 – 31/12/2017 | 51 t. | 1.1 mio. | 52 t. | -12 t. | 0 |
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Resistance Oncology ApS is 36945125.
Resistance Oncology ApS is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS.
The management of Resistance Oncology ApS consists of Kasper Pasternak Jørgensen and Nils Aage Brünner.
In 2025, Resistance Oncology ApS reported a gross profit of DKK -410,610.
Resistance Oncology ApS had 0 employees in 2016 according to the Danish CVR register.
Resistance Oncology ApS was founded on 1 July 2015.
Claim this page to add your logo and social links. Free to get started.
As of September 1, 2026, TIMPCO-RO ApS is registered as an owner of Resistance Oncology ApS with an ownership share of 25%.
Resistance Oncology ApS has published its annual report for 2025. Gross profit came to DKK -410,610, and the net result was DKK -665,070.
As of January 5, 2026, Pasternak Holding ApS is registered as an owner of Resistance Oncology ApS with an ownership share of 50%.
Resistance Oncology ApS has published its annual report for 2024. Gross profit came to DKK -15,712, and the net result was DKK -29,048.
As of June 26, 2025, Alexander Meier Holding ApS is registered as an owner of Resistance Oncology ApS with an ownership share of 5%.
On November 18, 2024, the company changed its name from 3B-Oncology ApS to Resistance Oncology ApS.
Resistance Oncology ApS has published its annual report for 2023. Gross profit came to DKK -21,005, and the net result was DKK -22,028.
On August 25, 2023, the company changed its name from Cortris Nordic ApS to 3B-Oncology ApS.
Resistance Oncology ApS has published its annual report for 2022. Gross profit came to DKK -11,970, and the net result was DKK -10,252.
As of September 1, 2022, Nils Aage Brünner is registered as director of Resistance Oncology ApS.
Resistance Oncology ApS has published its annual report for 2021. Gross profit came to DKK -10,140, and the net result was DKK -8,615.
As of July 6, 2022, Kasper Pasternak Jørgensen is registered as director of Resistance Oncology ApS.
As of July 6, 2022, Jørgen Peter Jørgensen has stepped down as director of Resistance Oncology ApS.
Resistance Oncology ApS has published its annual report for 2020. Gross profit came to DKK -9,500, and the net result was DKK -7,652.
Resistance Oncology ApS has published its annual report for 2019. Gross profit came to DKK 13,935, and the net result was DKK 9,885.
Resistance Oncology ApS has published its annual report for 2018. Gross profit came to DKK -14,500, and the net result was DKK -12,643.
Resistance Oncology ApS has published its annual report for 2017. Gross profit came to DKK 51,356, and the net result was DKK 1,147,497.
Resistance Oncology ApS has published its interim report for the period July 1, 2015 – December 31, 2016.
As of December 21, 2016, Jørgen Peter Jørgensen is registered as director of Resistance Oncology ApS.
As of December 21, 2016, Morten Fadum Nissen has stepped down as director of Resistance Oncology ApS.
As of December 21, 2016, Kasper Pasternak Jørgensen has stepped down as director of Resistance Oncology ApS.
As of July 2, 2015, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Resistance Oncology ApS.
As of July 2, 2015, Morten Fadum Nissen is registered as director of Resistance Oncology ApS.
As of July 2, 2015, Kasper Pasternak Jørgensen is registered as director of Resistance Oncology ApS.
As of July 2, 2015, Peter Andreas Stakemann has stepped down as adm. dir. of Resistance Oncology ApS.
On July 2, 2015, the company changed its name from ApS STAKE nr. 5237 to Cortris Nordic ApS.
As of July 1, 2015, Peter Andreas Stakemann is registered as adm. dir. of Resistance Oncology ApS.
Resistance Oncology ApS was founded on July 1, 2015.
Companies in the same industry and area
CVR 41183144
CVR 35451307
CVR 36392398
CVR 14479880
CVR 29625867
